Delcath Systems Inc

DCTHNASDAQ · USD
18.79USD0.00 (-2.34%)
6610

Delcath Systems Inc (DCTH) Option Chain

Delcath Systems Inc trades at $18.79, down 2.34%, with an IV Rank of 20.24%. This is low versus the past year, and the company carries a market cap of $654M in the Medical Devices industry. On the Dec 18, 2026 chain, the at the money $20.00 strike shows calls at $0.10 / $1.65 and puts at $1.65 / $2.75, both carrying about $0.93 of extrinsic value. The call has a 65.85% probability of expiring out of the money, and the put has 34.15%. Volume is heaviest on the $17.50 calls, at 5 contracts, and the $20.00 puts, at 4, as of Nov 20, 2026.

Read more

Tracking the DCTH option chain helps you see every strike and expiry on Delcath Systems Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of DCTH options activity at a glance. Use our scanner to monitor the DCTH option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For DCTH stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where DCTH options are being actively traded, and where they are not.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.

2026-12-18
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
13.212200.513.792.805.8015.00-20.17—1.150.001.1502486.79
38.235450.891.291.902.4517.50-6.87—1.200.001.200261.77
65.852800.880.000.101.6520.00+6.441.652.751.210.99410434.15
84.9118101.500.00—1.5022.50+19.741.604.903.71-0.460015.09
94.425501.650.00—1.6525.00+33.054.007.506.21-0.46005.58

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryMedical Devices
  • SectorHealthcare
  • IV Rank20.24% Low
  • Market cap (M$)654
  • 52 weeks high-16.53%
  • 52 weeks low121.58%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$28.33
    50.77% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-09
  • P/E121.30
  • Future P/E107.03
  • EPS (ttm)0.15
  • EPS growth next 5 years82.89%

As of Nov 20, 2026